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Abstract
Xeroderma pigmentosum (XP) is a rare autosomal recessive disorder characterized by extreme sensitivity to actinic
pigmentation changes in the skin and increased incidence of skin cancer. In some cases, patients are affected by
neurological alterations. XP is caused by mutations in 8 distinct genes (XPA through XPG and XPV). The XP-V (variant)
subtype of the disease results from mutations in a gene (XPV, also named POLH) which encodes for Polg, a member of the
Y-DNA polymerase family. Although the presence and severity of skin and neurological dysfunctions differ between XP
subtypes, there are overlapping clinical features among subtypes such that the sub-type cannot be deduced from the
clinical features. In this study, in order to overcome this drawback, we undertook whole-exome sequencing in two XP sibs
and their father. We identified a novel homozygous nonsense mutation (c.897T.G, p.Y299X) in POLH which causes the
disease. Our results demonstrate that next generation sequencing is a powerful approach to rapid determination of XP
genetic etiology.
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Introduction
Xeroderma pigmentosum (XP) is a rare autosomal recessive
disorder which affects 1/250.000 to 2.3/million individuals in
Western countries [1,2]. Higher incidence has been reported in
specific regions, such as Japan (1:20.000) and Tunisia (1:10.000)
[3,4]. XP patients are affected by extreme sensitivity to actinic
pigmentation changes in the skin and increased incidence of skin
cancer. Some patients display neurological alterations such as loss
of intellectual functioning, progressive hearing loss, neuromuscular
degeneration and tumors of the central nervous system [5,6]. XP is
caused by mutations in 8 distinct genes (named XPA through XPG
and XPV), which encode proteins that participate, excepting for
XPV, in the nucleotide excision repair (NER) molecular cascade
[2]. The NER system is responsible for repairing DNA damage
resulting from environmental factors, such as UV radiation and
carcinogenic chemical molecules [7]. This multistep mechanism
excises and eliminates damaged nucleotides followed by filling in
of the consequent gap, using the complementary DNA strand as a
template. Consequently, patients carrying NER molecular dys-
functions exhibit a wide spectrum of phenotypic features,
including XP [8].
The XP-V (variant) subtype of the disease results from
mutations in a gene (XPV, also named POLH) that is not involved
with the NER pathway. POLH encodes for Polg, a member of the
Y-DNA polymerase family, which is implicated in the synthesis of
DNA after injury (translesion synthesis process) [9–11]. Indeed, in
XP-V cells POLH mutations reduce the ability to replicate DNA
after UV exposure [12,13].
Although the presence and severity of skin and neurological
dysfunctions differ between XP subtypes, there are overlapping
clinical features among subtypes such that the sub-type cannot be
deduced from the clinical features.
In this study, in order to overcome this drawback, we undertook
whole-exome sequencing in two XP sibs and their father. We
identified a novel homozygous nonsense mutation (c.897T.G,
p.Y299X) in POLH which causes the disease. Our results
demonstrate that next generation sequencing is a powerful
approach to rapid determination of XP genetic etiology.
Materials and Methods
Patients
Patients (P1-II:2, P2-II:4) are sibs who attended the Dermatol-
ogy Unit of the Carlos Ardila Lulle Clinic of Bucaramanga
(Colombia) (Figure 1). We could not obtain clinical data and
biological samples from patient 3 (P3-II:7) but his family indicated
that he is affected by a similar phenotype (see below). This study
has been approved by the Ethical Committee at Universidad del
Rosario and was conducted according to the Declaration of
Helsinki Principles. Patients and their parents (C1-father, C2-
mother) provided a written consent form to participate in the
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study, which includes an authorization to publish these case
details.
The patients’ parents were reported to be consanguineous (first
cousins). P1 is a 38-year-old female who presented numerous sun-
induced skin changes since infancy. At the age of 21 years she
presented a unique skin lesion, located on the dorsal region of the
nose, which was diagnosed as a squamous cell carcinoma. Since
then, 4 additional tumors (basal cell carcinomas) have been
diagnosed and surgically resected. No antecedents of melanoma or
further neoplasias were recorded. At the age of 37 years physical
examination of the skin displayed: Fitzpatrick phototype III,
xerosis, multiple telangiectasias and hyper and hypo pigmented
lenticular macules (2 mm–5 mm). These lesions were especially
located on UV exposed regions, such as face, upper limbs, feet,
legs and upper thorax. Additionally, she displayed plaques of
keratosis located on the face, arms and legs. Palm and soles, scalp,
mucosae and nervous system were unaffected.
P2 (P19s sister) is a 36-year-old individual affected, since early
infancy, by significant photosensitivity related to the occurrence of
skin pigmented lesions, which develop on the sunlight exposed
areas of the body. Between 31–36 years of age, six basal cell and
one squamous cell carcinomas were diagnosed. Physical exami-
nation of the skin, performed at 36 years of age, displayed similar
findings to those observed in her sister, excepting for the presence
of 3 lesions suggestive of basal cell carcinoma.
Exome Capture and High-throughput Sequencing
Genomic DNAs from patients (P1 and P2) and their parents (C1
and C2) were extracted from whole blood samples using standard
procedures. Three micrograms of genomic DNA from P1, P2 and
C1 was made up to 130 ml with nuclease free water and sonicated
to fragment DNA into size ranging between 100 base pairs (bp) to
200bp (Covaris S220). The size distribution was checked by
running an aliquot of the sample on Agilent HS Bioanalyzer Chip.
The fragmented DNA was size selected using Agencourt AMPure
XP SPRI beads (Beckman Coulter). Subsequently, genomic DNA
libraries were constructed according to the SureSelect Target
Enrichment System protocol using SureSelect Library prep kit
(Agilent). DNA was subjected to a series of enzymatic reactions
that repair frayed ends, phosphorylate the fragments, add a single
nucleotideA overhang and ligate adaptors. After ligation, PCR
amplification (5 cycles) was performed to enrich the adaptor-
ligated fragments. The prepared libraries were then kept for
hybridization as outlined in SureSelect Target Enrichment System
for SOLiD 5500 Multiplexed Sequencing protocol. Hybridized
library fragments were isolated by magnetic capture using
Magnetic Streptavidin coated beads. PCR amplification (8 cycles)
was carried out to amplify the captured library and cleaned up
using AMPure XP beads (Beckman Coulter). An aliquot of the
captured library was run on Agilent High Sensitivity Bioanalyzer
Chip (Agilent).
Reference Genome and RefSeq Database
We used the human reference genome GRCh37/hg19 for
mapping exome-sequencing (Exome-Seq). The RefSeq sequence
database downloaded from NCBI on 12 May 2011 was used as
our gene model and for determining aminoacid substitutions.
Exome-Seq Processing-Read Mapping, Variant Calling
and Effect Determination
Raw data was obtained from the SOLiD55006l sequencer and
subjected to quality check and filtering using SAET (SOLiD
Accuracy Enhancement Tool, LifeScope suite). The high quality
filtered data were aligned with human reference genome and
variants were called against (LifeScope suite). Then, variations (vcf.
file) were transferred to local linux machine. Using snpEFF
(sourceforge) the filtered variations were classified, based on their
function, into distinct categories such as synonymous, non-
synonymous, nonsense, missense, insertions, deletions and splice
variations.
Results were further compared with the dbSNP database
combining NCBI version 129 to db 137. This helped to identify
novel variations and potential deleterious effects using snpSIFT/
snpEff. Finally, the annotated variations were further reviewed
manually. Exome sequencing assays were performed at Genotypic
Technology (Bangalore, Karnataka, India).
POLH Direct Sequencing
In P1, P2, C1 and C2 the exon 8 coding sequence of POLH
(ENST00000372236) was amplified using exon-flanking oligonu-
cleotides. Amplicons were purified using shrimp alkaline phos-
phatase and exonulease I, and sequenced with internal primers.
Primer sequences and PCR conditions are available on request.
The new sequence data has been deposited in the NCBI-dbSNP
database under the accession number rs190423114.
Figure 1. Pedigree of the XP family. Black symbols refer to affected individuals. Black dots into first generation individuals symbols (I:1 and I:2)
represents the POLH c.897T.G mutation at heterozygous state.
doi:10.1371/journal.pone.0064692.g001
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Results
We generated 21 GB data for 3 samples for each individual as
paired-end, 75 bases forward and 35 bases reverse, and about 76–
85% (38.90–43.51 Mb in length) of the targeted bases were
covered at 20X coverage, which sufficiently passed our thresholds
for calling SNPs and short insertions or deletions (indels). The
bases with quality scores above 20 (99% accuracy of a base call)
represent over 79–86% of total sequence data.
Exome-Seq processing showed that patients and C1 are
respectively homozygous and heterozygous for the POLH
c.897T.G (p.Y299X) mutation. Direct sequencing of POLH exon
8 confirmed these findings. We did not find potential etiological
non-synonymous variants in any of the other XP genes.
Discussion
At present, XP patients are classified into eight distinct subtypes
depending on the occurrence of mutations in specific genes.
However, it has been described that,6% of XP cases do not carry
mutations in XPA-G or XPV, which suggest potential promoter
regulatory variants as well as undiscovered etiological genes that
could be identified using direct sequencing or NGS technology [5].
In this context, it would be interesting to sequence, via NGS, XP
patients from previous reports who lack mutations in XPA through
XPG and XPV genes.
Although the majority of subtypes implicate dysfunctions of
proteins which participate in the NER molecular pathway,
overlapping clinical features among patients have been observed.
Furthermore, the clinical presentation of XPV can be similar to
that observed in patients carrying XP-NER gene mutations. For
instance, although most XP-V, XP-C and XP-E patients (which
represent in Europe and the United States 40–58% of all XP cases)
lack severe sunburn reactions, some cases display extreme
phenotypes [2,14,15]. Mutations in XPC and XPE subtypes,
which usually do not lead to neurological disease, can present
central nervous system abnormalities due genetic and environ-
mental modifier factors [2,16,17]. XPV patients (who are rarely
affected by neurological abnormalities) can exhibit skin injuries
that vary considerably in severity [18].
In this context, selection of a particular candidate gene for direct
sequencing remains difficult. In addition, direct sequencing of all
XP coding regions from genomic DNA might be challenging as
they encompass more than 100 exons (,25 kilobases). Whole-
exome sequencing has led to the identification of a considerable
number of pathogenic mutations in monogenic mendelian
disorders, including skin pathologies [19–22]. This approach is
especially useful for investigating recessive pathologies, as com-
parative analysis of coding sequence variations between affected
and non-affected individuals enable the efficient identification of
homozygous causative mutations [23].
Clinically, P1 and P2 are affected by a mild form of the disease
since they have been affected by less than 10 skin tumors, which
appeared after the age of 20. In addition, since our patients lack
neurological dysfunction, we predicted that the disease pathology
most likely resulted from coding mutations in XPC, XPE or XPV.
Coding regions of these genes encompass 37 exons, which may be
sequenced, in a single patient, via direct sequencing or NGS at
similar costs. Indeed, at present primer synthesis and direct
sequencing of 20 exons using internal oligonucleotides display
similar costs to a single exome sequencing experiment. Further-
more, PCR amplification and Sanger sequencing of a significant
number of exons may be labour-intensive.
It is important to note that, at present, downstream bioinfor-
matic analysis of sequencing data is considered as the bottleneck of
NGS techniques. Whole-genome and exome sequencing generate
a considerable amount of data, which has to be quality controlled,
filtered and interpreted in a biological context. This analysis
implicates significant computational costs and needs a particular
expertise. Although distinct bioinformatics tools have been
developed in order to analyze and interpret the increasing amount
of sequencing data, sensitivity and efficiency to accurately map
noisy reads depends of several factors, such as the choice of single
or pair-end reads, the use of long or short reads and the
sequencing depth [24]. In this context, the setup of a reliable NGS
platform takes a considerable period of time and may represent
high costs. Additionally, it has been reported that NGS sensitivity
may be low to find somatic mutations [25]. However, very recent
reports indicate that this approach may display ,90% of
sensitivity to identify germline mutations [26,27]. In the present
report we have used a similar NGS approach to that described in a
previous study, which led us to identify a novel gene related to
pachydermoperiostosis/myelofibrosis etiology [28].
Our sequencing experiments revealed that the previously
unknown POLH p.Y299X mutation is causative of the phenotype.
Up to now, more than 50 POLH mutations have been associated
with XPV pathogenesis [4,10,18,29–33]. In a significant propor-
tion of cases these mutations lead to the synthesis of mRNA
molecules carrying a premature stop codon, which might be
degraded by the nonsense-mediated decay (NMD) system [18]. In
our case, since the premature stop codon is situated at least 50
nucleotides upstream of an exon-exon boundary, we propose that
mutant mRNAs might be recognized and degraded by the NMD
machinery [34]. In addition, the POLH c.897T.G mutation is
predicted to generate a truncated protein of 299 residues lacking
the C-terminal region of the highly conserved N-terminal domain
of the protein, which comprises the enzymatic active site
[31,35,36]. Therefore, as suggested for other nonsense biallelic
mutations which truncate the N-terminal protein region, it is
highly likely that the POLH- p.Y299X mutant protein lacks
biological activity [31].
Taken together, our results demonstrate that whole-exome
sequencing is a powerful strategy, which might be used in a near
future, for XP molecular etiology determination. Furthermore,
they add information on the clinical and molecular characteristics
of XPV patients.
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